
Robert L. Nasser
Examiner (ID: 11561, Phone: (571)272-4731 , Office: P/3992 )
| Most Active Art Unit | 3736 |
| Art Unit(s) | 3736, 3311, 3735, 3992, 3305 |
| Total Applications | 2167 |
| Issued Applications | 1546 |
| Pending Applications | 257 |
| Abandoned Applications | 371 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20671864
[patent_doc_number] => 12612364
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-28
[patent_title] => Salts and solid forms of 4-hydroxy-
[patent_app_type] => utility
[patent_app_number] => 19/408193
[patent_app_country] => US
[patent_app_date] => 2025-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 32008
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19408193
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/408193 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | Dec 2, 2025 | Issued |
Array
(
[id] => 20335421
[patent_doc_number] => 20250339541
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 19/192108
[patent_app_country] => US
[patent_app_date] => 2025-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84686
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 351
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19192108
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/192108 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Apr 27, 2025 | Pending |
Array
(
[id] => 20098847
[patent_doc_number] => 20250228783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 19/172172
[patent_app_country] => US
[patent_app_date] => 2025-04-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42632
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19172172
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/172172 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | Apr 6, 2025 | Issued |
Array
(
[id] => 20083763
[patent_doc_number] => 20250213699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-03
[patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 19/081876
[patent_app_country] => US
[patent_app_date] => 2025-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84964
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 366
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19081876
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/081876 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Mar 16, 2025 | Pending |
Array
(
[id] => 20120411
[patent_doc_number] => 20250235442
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-24
[patent_title] => Piperidine Urea Derivatives for Use as Inotropic Agents
[patent_app_type] => utility
[patent_app_number] => 19/060522
[patent_app_country] => US
[patent_app_date] => 2025-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5874
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19060522
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/060522 | Piperidine urea derivatives for use as inotropic agents | Feb 20, 2025 | Issued |
Array
(
[id] => 20057327
[patent_doc_number] => 20250195549
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-19
[patent_title] => NEW USE
[patent_app_type] => utility
[patent_app_number] => 18/972566
[patent_app_country] => US
[patent_app_date] => 2024-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18972566
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/972566 | NEW USE | Dec 5, 2024 | Pending |
Array
(
[id] => 19447416
[patent_doc_number] => 20240307546
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/653655
[patent_app_country] => US
[patent_app_date] => 2024-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88162
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 391
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653655
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/653655 | ASGPR-binding compounds for the degradation of extracellular proteins | May 1, 2024 | Issued |
Array
(
[id] => 19915222
[patent_doc_number] => 12290568
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-06
[patent_title] => ASGPR-binding compounds for the degradation of extracellular proteins
[patent_app_type] => utility
[patent_app_number] => 18/653610
[patent_app_country] => US
[patent_app_date] => 2024-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 138
[patent_figures_cnt] => 162
[patent_no_of_words] => 85073
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 353
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653610
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/653610 | ASGPR-binding compounds for the degradation of extracellular proteins | May 1, 2024 | Issued |
Array
(
[id] => 19402080
[patent_doc_number] => 20240285591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)
[patent_app_type] => utility
[patent_app_number] => 18/628353
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20023
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628353
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/628353 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | Apr 4, 2024 | Abandoned |
Array
(
[id] => 19343499
[patent_doc_number] => 20240252462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/627708
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21379
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627708
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/627708 | Methods of providing solriamfetol therapy to subjects with impaired renal function | Apr 4, 2024 | Issued |
Array
(
[id] => 19510456
[patent_doc_number] => 20240342142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-17
[patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)
[patent_app_type] => utility
[patent_app_number] => 18/628366
[patent_app_country] => US
[patent_app_date] => 2024-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628366
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/628366 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | Apr 4, 2024 | Abandoned |
Array
(
[id] => 19367349
[patent_doc_number] => 12059409
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-08-13
[patent_title] => Pharmaceutical composition for modified release
[patent_app_type] => utility
[patent_app_number] => 18/613270
[patent_app_country] => US
[patent_app_date] => 2024-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 9700
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613270
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/613270 | Pharmaceutical composition for modified release | Mar 21, 2024 | Issued |
Array
(
[id] => 19331355
[patent_doc_number] => 20240245785
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
[patent_app_type] => utility
[patent_app_number] => 18/584914
[patent_app_country] => US
[patent_app_date] => 2024-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88113
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584914
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/584914 | ASGPR-binding compounds for the degradation of extracellular proteins | Feb 21, 2024 | Issued |
Array
(
[id] => 19249159
[patent_doc_number] => 20240200146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
[patent_app_type] => utility
[patent_app_number] => 18/516552
[patent_app_country] => US
[patent_app_date] => 2023-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34472
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18516552
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | Nov 20, 2023 | Pending |
Array
(
[id] => 19996628
[patent_doc_number] => 20250134850
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-01
[patent_title] => PLANT-DERIVED SMALL MOLECULES AS MARBURG VIRUS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/499733
[patent_app_country] => US
[patent_app_date] => 2023-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499733
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/499733 | PLANT-DERIVED SMALL MOLECULES AS MARBURG VIRUS INHIBITORS | Oct 31, 2023 | Pending |
Array
(
[id] => 18987750
[patent_doc_number] => 20240059719
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => GOLD COMPLEXES AS ANTICANCER AGENT
[patent_app_type] => utility
[patent_app_number] => 18/383517
[patent_app_country] => US
[patent_app_date] => 2023-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383517
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/383517 | GOLD COMPLEXES AS ANTICANCER AGENT | Oct 24, 2023 | Pending |
Array
(
[id] => 18953490
[patent_doc_number] => 20240041817
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/486623
[patent_app_country] => US
[patent_app_date] => 2023-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21551
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486623
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/486623 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | Oct 12, 2023 | Abandoned |
Array
(
[id] => 19279874
[patent_doc_number] => 20240216346
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same
[patent_app_type] => utility
[patent_app_number] => 18/376983
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39229
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376983
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/376983 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | Oct 4, 2023 | Pending |
Array
(
[id] => 18860064
[patent_doc_number] => 20230414498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS
[patent_app_type] => utility
[patent_app_number] => 18/244500
[patent_app_country] => US
[patent_app_date] => 2023-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57965
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244500
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/244500 | Methods of treating eosinophilic esophagitis | Sep 10, 2023 | Issued |
Array
(
[id] => 19155998
[patent_doc_number] => 20240148704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-09
[patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)
[patent_app_type] => utility
[patent_app_number] => 18/241355
[patent_app_country] => US
[patent_app_date] => 2023-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20010
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18241355
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/241355 | METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) | Aug 31, 2023 | Pending |